

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

PAR PHARMACEUTICAL, INC.,
Petitioner

v.

HORIZON THERAPEUTICS, LLC,
Patent Owner

Case IPR2017-01769
Patent 9,326,966

PATENT OWNER'S INITIAL MANDATORY NOTICES

Pursuant to 37 C.F.R. § 42.8(a), the Patent Owner submits the following initial mandatory notices.

1. Real Parties-In-Interest (37 C.F.R. § 42.8(b)(1))

U.S. Patent No. 9,326,966 is owned by Horizon Therapeutics, LLC (f/k/a Hyperion Therapeutics, Inc.), a company organized and existing under the laws of the State of Delaware, having its principal place of business at 150 S. Saunders Road Lake Forest, IL 60045. Pursuant to the requirements of 37 C.F.R. § 42.8(b)(1), the undersigned state that the real parties-in-interest are Horizon Therapeutics, LLC as well its corporate parents (collectively, Horizon):

- Horizon Pharma, Inc., a corporation organized and existing under the laws of the State of Delaware having its principal place of business at 150 S. Saunders Road Lake Forest, IL 60045, which is wholly owned by;
- Horizon Pharma Finance S.á.r.l., an entity organized and existing under the laws of Luxembourg, having its principal place of business at 19 Rue de Bitbourg, Luxembourg, which is wholly owned by;
- Horizon Pharma Capital Limited, a corporation organized and existing under the laws of Ireland, having its principal place of business at Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, Ireland, which is wholly owned by;

- Horizon Pharma Holdings Limited, a corporation organized and existing under the laws of Ireland, having its principal place of business at Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, Ireland, which is wholly owned by; and
- Horizon Pharma plc, a corporation organized and existing under the laws of Ireland, having its principal place of business at Connaught House, 1st Floor, 1 Burlington Road, Dublin 4, Ireland.

2. Related Matters (37 C.F.R. § 42.8(b)(2))

The following judicial and administrative matters may affect or be affected by a decision in this proceeding:

- (a) IPR2015-01117, petition filed April 29, 2015, by the present Petitioner, directed at U.S. Patent No. 8,642,012, which is also owned by Horizon Therapeutics, LLC and has one common inventor with the patent at issue in this case. The Board instituted trial in an institution decision dated November 4, 2015 and issued a final written decision on November 3, 2016.
- (b) IPR2015-01127, petition filed April 29, 2015, by the present Petitioner, directed at U.S. Patent 8,404,215, which is the great-grandparent of the patent at issue in this case. The Board instituted

trial in an institution decision dated November 4, 2015 and issued a final written decision on September 29, 2016.

- (c) IPR2016-00283, directed at U.S. Patent No. 8,642,012. The petition was filed December 4, 2015 by Lupin Ltd. and Lupin Pharmaceuticals Inc. and joined with IPR2015-01117.
- (d) IPR2016-00284, directed at U.S. Patent 8,404,215. The petition was filed December 4, 2015 by Lupin Ltd. and Lupin Pharmaceuticals Inc. and joined with IPR2015-01127.
- (e) IPR2016-00829, directed at U.S. Patent 9,095,559, which is the grandparent of the patent at issue in this case. The petition was filed April 1, 2016 by Lupin Ltd. and Lupin Pharmaceuticals Inc. The Board instituted trial in an institution decision dated September 30, 2016, and oral argument was held July 28, 2017.
- (f) IPR2017-01159, directed at U.S. Patent 9,254,278, which is the parent of the patent at issue in this case. The petition was filed March 27, 2017 by Lupin Ltd. and Lupin Pharmaceuticals Inc.
- (g) IPR2017-01160, directed at U.S. Patent 9,326,966, which is the patent at issue in this case. The petition was filed March 27, 2017 by Lupin Ltd. and Lupin Pharmaceuticals Inc.

- (h) IPR2017-01767, petition filed the same date as this petition, by the present Petitioners, directed at U.S. Patent 9,254,278, which is the parent of the patent at issue in this case.
- (i) IPR2017-01768, petition filed the same date as this petition, by the present Petitioners, directed at U.S. Patent 9,095,559, which is the grandparent of the patent at issue in this case.
- (j) *Par Pharmaceutical, Inc. v. Horizon Therapeutics, LLC*, Appeal No. 2017-1451 to the Federal Circuit from the Board's Final Written Decision in IPR Nos. IPR2015-01117 and IPR2016-00283 concerning U.S. Patent No. 8,642,012.
- (k) *Hyperion Therapeutics Inc. v. Par Pharmaceutical, Inc.*, Civil Action No. 2:14-cv-00384-JRG-RSP (E.D. Tex. filed April 23, 2014). The Complaint asserts infringement of U.S. Patent Nos. 8,404,215 and 8,642,012. On December 14, 2015, the district court stayed that case pending resolution of IPRs. On March 30, 2017, the district court continued the stay pending the resolution of Par's Appeal No. 2017-1451.
- (l) *Horizon Therapeutics Inc. v. Par Pharmaceutical Inc.*, Civil Action No. 1:16-cv-3910-RBK-JS (D.N.J. filed June 30, 2016). The

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.